Ignite Creation Date:
2024-05-05 @ 5:31 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00474513
Status:
COMPLETED
Last Update Posted:
2012-06-04
First Post:
2007-05-15
Brief Title:
An Imaging Study to Investigate the Distribution of GSK239512 in the Brain
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A PET Study Using 11C GSK189254 to Establish the Dose Plasma Concentration and Brain Receptor Occupancy Relationship of GSK239512 a Histamine H3 Antagonist in Healthy Subjects
Status:
COMPLETED
Status Verified Date:
2011-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
GSK239512 is being developed for the treatment of symptoms of cognitive impairment in many diseases GSK239512 is a drug that binds to the Histamine 3 receptor a protein in the brain receptor occupancy This study will use the technique of positron emission tomography PET as an imaging tool to highlight areas of the brain that GSK239512 has penetrated and subsequently bound to receptors after receiving an oral dose of the drug It will also look at the rate the drug dissociates from the receptors in the brain Results from the study will provide information on doses of the drug to be given in further studies
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None